Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors.

Of note, when Ctrl was matched to Riva, corrected Kaplan-Meier analyses during the total FU revealed highly significant differences for both endpoints: rates of hospitalization for new-onset of AF ( Figure 1 , p < 0.001) as well as rates of SCD ( Figure 2 , p < 0.001). 4 Discussion The COVID-19 pandemic led to a burgeoning population of patients recovering from SARS-CoV-2 infection and is still affecting healthcare systems worldwide.

also in 132,142 other papers